Karyopharm Therapeutics To Host Conference Call On June 2 To Discuss Results From Phase 3 SENTRY Trial Of Selinexor Plus Ruxolitinib In Myelofibrosis And To Follow Dr. Mascarenhas' Oral Presentation Of Results At 2026 ASCO Annual Meeting

Benzinga Newsdesk www.benzinga.com Neutral 90.5%

Neg 0% Neu 90.5% Pos 0%

Comments

No comments yet. Be the first!